Innate Pharma : Lacutamab: partial clinical hold, TELLOMAK results still expected in Q4 2023
>FDA places a clinical hold following suspicion of a serious side effect - Innate Pharma this morning gave an update on its lacutamab clinical programme currently in phase II (TELLOMAK) in the treatment of Sézary syndrome and mycosis fungoides and in phase Ib in peripheral T-cell lymphoma. The company announced the FDA’s decision to place a partial clinical hold on the programme leading to a pause in new patient enrolment in the ongoing lacutamab trials following one ...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.